NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

Core Points - NovaBay Pharmaceuticals has regained compliance with the NYSE American's continued listing standards as of October 20, 2025 [1][4] - The company was previously notified of non-compliance on April 18, 2024, and May 28, 2024, due to insufficient stockholders' equity [2] - NovaBay raised approximately $6.0 million through the issuance of pre-funded warrants and an additional $2.15 million from the sale of Series E non-voting convertible preferred stock, bringing its stockholders' equity above the required $6 million [3] Company Background - NovaBay Pharmaceuticals focuses on the development and sale of scientifically created and clinically proven products in eyecare, wound care, and skin care [5]